Insulin

More documents

Recommendations

Info

UKPDS demonstrated loss of glycemiccontrol with all agents studied9HbA 1c(%)87ConventionalGlyburideChlorpropamideMetformin<strong>Insulin</strong>600Overweight patientscohort, median values2 4 6 8 10Years from randomizationUpper limit of of normal = 6.2%UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854–865.
Page 6 and 7: Milestones for Management of Diabet
Page 8 and 9: GLOBAL PROJECTIONS FORTHE DIABETES
Page 10 and 11: ILLNESS• Absence of symptoms• I
Page 14 and 15: The UKPDS demonstrated progressived
Page 16 and 17: UKPDS 35 - Association of glycemia
Page 18 and 19: Type 2 DiabetesImplications of Prog
Page 20 and 21: OADs - 5 classificationsSulphonylur
Page 22 and 23: Oral antidiabetic agents: sideeffec
Page 24 and 25: Monotherapy and Combination Therapy
Page 26 and 27: DiagnosisLifestyle intervention + m
Page 28 and 29: Incretins: augment insulin secretio
Page 30 and 31: The Incretin : Where they go?• Bo
Page 32 and 33: GLP-1: effects on the β-cellGlucos
Page 35 and 36: Incretin-based therapies• GLP-1 1
Page 37 and 38: Target for Control? 6.5%? 7.0%Indiv
Page 39 and 40: STENO-2 STUDY160 patients with T2D
Page 41 and 42: STENO-2: Follow up at 8 yrsConventi
Page 43 and 44: Steno -2: Cardiovascular endpointsa
Page 45 and 46: PATIENT FACTORS• Poor acceptance
Page 47 and 48: MANAGEMENT• Patient education { d
Page 49 and 50: MULTIDISCIPLINARY CARE• Primary h
Page 52 and 53: Thank You

Insulin

Create successful ePaper yourself

Delete template?

Save as template?